Role of the oxygen-dependent degradation domain in a hypoxia-inducible gene expression system in vascular endothelial growth factor gene therapy

Spine

Volumn 34, Issue 26, 2009, Pages

  Jin, Honglian ^a   Liu, Meng Lu ^a,b   Kim, Hyun Ah ^c   Lee, Minhyung ^c   An, Sungsu ^a,b   Oh, Jinsoo ^a,b   Cho, Joon ^d   Yi, Seong ^a   Kim, Keungnyun ^a   Yoon, Doheum ^a,b   Ha, Yoon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Hanyang University   (South Korea)

^d Konkuk University Hospital   (South Korea)

Author keywords

Gene therapy; Hypoxia inducible gene expression system; Oxygen dependent degradation; Spinal cord injury; Vascular endothelial growth factor

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PLASMID DNA; VASCULOTROPIN;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; ENHANCER REGION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE THERAPY; HYPOXIA; MOUSE; NERVE CELL; NEUROBLASTOMA CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; REOXYGENATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD INJURY; THORACIC SPINAL CORD;

ANIMALS; ANOXIA; ASTROCYTES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE THERAPY; GENES, REPORTER; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD INJURIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 74249109032     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181c4af80     Document Type: Article

References (30)

1. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 2003;10: 285-291
2. Isner JM. Myocardial gene therapy. Nature 2002;415:234-239
3. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 2004;109:2487-2491 (Pubitemid 38720544)
4. Brockington A, Lewis C, Wharton S, et al. Vascular endothelial growth factor and the nervous system. Neuropathol Appl Neurobiol 2004;30:427-446
5. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue-beyond blood vessels. Exp Neurol 2004;187:246-253
6. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26:943-954
7. Lee M, Rentz J, Bikram M, et al. Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther 2003;10: 1535-1542 (Pubitemid 37063258)
8. Wang Y, Galvan V, Gorostiza O, et al. Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat. Brain Res 2006;1115:186-193
9. Wang YQ, Guo X, Qiu MH, et al. VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion. J Neurosci Res 2007;85:73-82.
10. Jiang J, Jiangl N, Gao W, et al. Augmentation of revascularization and prevention of plasma leakage by angiopoietin-1 and vascular endothelial growth factor co-transfection in rats with experimental limb ischaemia. Acta Cardiol 2006;61:145-153
11. Xiaowei H, Ninghui Z, Wei X, et al. The experimental study of hypoxiainducible factor-1alpha and its target genes in spinal cord injury. Spinal Cord 2006;44:35-43.
12. Choi UH, Ha Y, Huang X, et al. Hypoxia-inducible expression of vascular endothelial growth factor for the treatment of spinal cord injury in a rat model. J Neurosurg Spine 2007;7:54-60.
13. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102:898-901.
14. Springer ML, Chen AS, Kraft PE, et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998;2:549-558
15. Kim HA, Kim K, Kim SW, et al. Transcriptional and post-translational regulatory system for hypoxia specific gene expression using the erythropoietin enhancer and the oxygen-dependent degradation domain. J Control Release 2007;121:218-224
16. Lee M, Choi D, Choi MJ, et al. Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3-untranslated region for the VEGF gene therapy. J Control Release 2006;115:113-119
17. Lee M, Bikram M, OH S, et al. Sp1-dependent regulation of the RTP801 promoter and its application to hypoxia-inducible VEGF plasmid for ischemic disease. Pharm Res 2004;21:736-741
18. Lee M, Lee ES, Kim YS, et al. Ischemic injury-specific gene expression in the rat spinal cord injury model using hypoxia-inducible system. Spine 2005;30: 2729-2734
19. Stein I, Neeman M, Shweiki D, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995;15:5363-5368
20. Dibbens JA, Miller DL, Damert A, et al. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell 1999;10:907-919
21. Choi BH, Ha Y, Ahn CH, et al. A hypoxia-inducible gene expression system using erythropoietin 3′ untranslated region for the gene therapy of rat spinal cord injury. Neurosci Lett 2007;412:118-122
22. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
23. Skold MK, Marti HH, Lindholm T, et al. Induction of HIF1alpha but not HIF2alpha in motoneurons after ventral funiculus axotomy-implication in neuronal survival strategies. Exp Neurol 2004;188:20-32.
24. Lee JW, Bae SH, Jeong JW, et al. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 2004;36:1-12.
25. Liu ML, Liu MJ, Shen YF, et al. Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-{beta}. J Cell Sci 2009; 122:1917-1926.
26. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000;102:965-974
27. Sylven C, Sarkar N, Ruck A, et al. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron Artery Dis 2001;12:239-243
28. Carmeliet P, Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 2002;13:39-53.
29. Hansen TM, Moss AJ, Brindle NP. Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. Curr Neurovasc Res 2008;5:236-245
30. Skold MK, Kanje M. Vascular endothelial growth factor in central nervous system injuries-a vascular growth factor getting nervous? Curr Neurovasc Res 2008;5:246-259